Cardiovascular medicine – BJC TV

Key differences between Kerendia▼ (finerenone) and steroidal MRAs

jleiwy@omniamed.com — Fri, 19 Jun 2026 14:01:00 +0000

Prescribing information and adverse event reporting information for Kerendia^®▼(finerenone) can be found here.

Featuring

Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

References

Piccirillo F, Liporace P, Nusca A et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271–305.
Spironolactone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12015/smpc#gref.
Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8810/smpc.

DOWNLOAD OUR DOSING GUIDE

Exercise in cardiomyopathy: What happens after the consultation?

hginn@omniamed.com — Fri, 29 May 2026 10:18:16 +0000

Learning objectives:

To understand that exercise is possible for nearly all cardiomyopathy patients
To learn successful ways to tailor exercise for individual patients
To develop an understanding of the ACTIVE clinical approach and the four pillars of cardiovascular rehabilitation
To gain awareness of how to support patients safely with practical exercise prescription
To feel inspired to help patients manage their cardiovascular health with confidence

Speaker: Shane Purcell Clinical Exercise Physiologist, Imperial College Healthcare NHS Trust

Insights from the ESC Heart Failure Congress, 2026

jtaylor@omniamed.com — Fri, 15 May 2026 14:02:25 +0000

Learn more about some of the key sessions from the conference:

Cardiac amyloidosis: early diagnosis matters

Controversies in contemporary drug therapy for heart failure

How to crack the cardiorenal code: from clinical mastery to unit creation

Advances in cardiomyopathies

Debate: artificial intelligence in heart failure care, a great equaliser or a new divider?

Speaker

Dr Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospital Dorset

Living and dying well with heart failure – how can palliative care help?

jtaylor@omniamed.com — Wed, 06 May 2026 09:35:23 +0000

Learning objectives:

To understand the potential role of palliative care in supporting heart failure patients
To learn about down titrating some medications to improve symptom control and reduce side effects
To develop an understanding of advance care planning including DNACPR & ICD deactivation
To gain awareness of the ethical dilemmas that might arise
To feel inspired to develop relationships with your local palliative care providers and work together more closely

Speaker

Dr Sharon Chadwick, Consultant in Palliative Medicine, Hospice of St Francis, Berkhamsted, Hertfordshire

Exploring cardiac amyloidosis: Diagnosis, treatment, and best practices

jleiwy@omniamed.com — Tue, 31 Mar 2026 14:18:46 +0000

Studies report up to 18% (n/N = 9/49) of patients aged ≥60 years old with heart failure with preserved ejection fraction (HFpEF) had transthyretin amyloid cardiomyopathy (ATTR-CM), one of the main types of cardiac amyloidosis.¹ Clinical expert Dr Kate Gatenby highlights this and gives an overview of the causes, diagnosis and best practices in the management of patients with ATTR-CM.

Can artificial intelligence (AI) save UK primary care? An introduction into how digital healthcare may revolutionise and improve general practice.

hginn@omniamed.com — Mon, 02 Feb 2026 14:49:48 +0000

By watching this video, you can:

Gain an understanding of how AI works and what different types of AI programmes can do

Learn the difference between machine learning, large language processing and generative AI

Discover how the admin burden can be reduced by AI with earlier intervention, improved coding, and better patient understanding without additional workload

Explore the challenges and barriers to using this emerging technology

Speakers

Dr Martin Godfrey, GP, Clapham Family Practice, London

Dr Neil Paul, GP, Ashfields Primary Care Centre, Cheshire

Cardio-oncology in practice: bridging hospital & community – top tips for generalists

hginn@omniamed.com — Wed, 07 Jan 2026 12:48:48 +0000

- To understand the importance of cardio-oncology in today’s population of cancer patients
- To learn the three stages in the cancer journey and the role of generalists
- To develop an understanding of the current treatments for cancer and their possible impact on cardiac health
- To gain an awareness of the evolving need for cardio-oncology services in the UK and the role of the cardio-oncologist within an MDT

Speakers

Dr SivaTharshini Ramalingam GP Cardio-oncologist, Royal Brompton Hospital, London GP Partner, Oxted, Surrey

Rapid up-titration of heart failure therapies: practice strategies for adopting a STRONG-HF pathway in the UK

jleiwy@omniamed.com — Tue, 02 Dec 2025 16:10:12 +0000

To learn more about STRONG-HF and NT-proBNP testing click here.

References

Mebazaa A et al. Lancet 2022;400:1938–52

Digital transformations in cardiovascular medicine – where do we begin?

hginn@omniamed.com — Tue, 21 Oct 2025 12:54:05 +0000

Learn more about the role of AI in today’s clinics
Discover the pros and cons of electronic patient records and how important really is cybersecurity for hospitals?
Understand the future of wearables, and whether they help. Can virtual wards actually exist?
Explore the pressures faced by the NHS and its ability to cope with the changing digital landscape.
Consider how digital innovation might help us move from cure to prevention? What might new guidelines look like beyond 2025?

Speakers

Dr Sarah Hudson, Consultant Cardiologist, Wye Valley HNS Trust
Charles Lowe, CEO, Digital Health and Care Alliance (DHCA)

ESC Congress 2025 highlights – The latest trials and updated ESC guidelines: A UK perspective

hginn@omniamed.com — Mon, 29 Sep 2025 14:34:17 +0000

What is the role of beta-blockers in contemporary practice?
Do wearables and active monitoring for atrial fibrillation really work?
Controlled potassium levels: is hyperkalaemia a treatment effect or a side effect?
New valvular heart disease guidelines for 2025
A focused updated on dyslipidaemia

Speakers

Dr Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospital Dorset
Dr Ahmed Alsobhi, Cardiology Research Fellow, University Hospital of Southampton